441 related articles for article (PubMed ID: 29990498)
1. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.
Binder ZA; Thorne AH; Bakas S; Wileyto EP; Bilello M; Akbari H; Rathore S; Ha SM; Zhang L; Ferguson CJ; Dahiya S; Bi WL; Reardon DA; Idbaih A; Felsberg J; Hentschel B; Weller M; Bagley SJ; Morrissette JJD; Nasrallah MP; Ma J; Zanca C; Scott AM; Orellana L; Davatzikos C; Furnari FB; O'Rourke DM
Cancer Cell; 2018 Jul; 34(1):163-177.e7. PubMed ID: 29990498
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
3. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
4. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
6. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
[TBL] [Abstract][Full Text] [Related]
7. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
[TBL] [Abstract][Full Text] [Related]
8. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
9. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
10. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
11. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.
Gao X; Xia X; Li F; Zhang M; Zhou H; Wu X; Zhong J; Zhao Z; Zhao K; Liu D; Xiao F; Xu Q; Jiang T; Li B; Cheng SY; Zhang N
Nat Cell Biol; 2021 Mar; 23(3):278-291. PubMed ID: 33664496
[TBL] [Abstract][Full Text] [Related]
12. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Sarkaria JN; Yang L; Grogan PT; Kitange GJ; Carlson BL; Schroeder MA; Galanis E; Giannini C; Wu W; Dinca EB; James CD
Mol Cancer Ther; 2007 Mar; 6(3):1167-74. PubMed ID: 17363510
[TBL] [Abstract][Full Text] [Related]
13. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
Burley TA; Mączyńska J; Shah A; Szopa W; Harrington KJ; Boult JKR; Mrozek-Wilczkiewicz A; Vinci M; Bamber JC; Kaspera W; Kramer-Marek G
Int J Cancer; 2018 Jun; 142(11):2363-2374. PubMed ID: 29313975
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.
Pudełek M; Król K; Catapano J; Wróbel T; Czyż J; Ryszawy D
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443749
[TBL] [Abstract][Full Text] [Related]
16. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
17. Predicting epidermal growth factor receptor gene amplification status in glioblastoma multiforme by quantitative enhancement and necrosis features deriving from conventional magnetic resonance imaging.
Dong F; Zeng Q; Jiang B; Yu X; Wang W; Xu J; Yu J; Li Q; Zhang M
Medicine (Baltimore); 2018 May; 97(21):e10833. PubMed ID: 29794775
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
19. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
20. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
